Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Neonatology

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 100 articles: HTML format

Single Articles

November 2024
1. LOFBERG L, Abrahamsson T, Bjorklund LJ, Hellstrom Westas L, et al
   Respiratory support and bronchopulmonary dysplasia in infants born at 22-26 weeks gestation in Sweden, 2004-2007 and 2014-2016.
   Eur Respir J. 2024 Nov 7:2401203. doi: 10.1183/13993003.01203-2024.
   PubMed     Abstract available
   
   
   
2. LIN B, Gong J, Keenan K, Lin F, et al
   Genome-wide association study of susceptibility to Pseudomonas aeruginosa infection in cystic fibrosis.
   Eur Respir J. 2024;64:2400062.
   PubMed     Abstract available
   
   
   
3. CROMWELL EA, Ostrenga JS, Sanders DB, Morgan W, et al
   Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.
   Eur Respir J. 2024;64:2401146.
   PubMed     Abstract available
   
   
   October 2024
4. WANG G, Hallberg J, Merid SK, Kumar A, et al
   Body mass index trajectories from birth to early adulthood and lung function development.
   Eur Respir J. 2024 Oct 28:2400298. doi: 10.1183/13993003.00298-2024.
   PubMed     Abstract available
   
   
   
5. URBANTAT RM, Mall MA
   How many functioning ciliated airway epithelial cells are necessary for effective mucociliary clearance?
   Eur Respir J. 2024;64:2401573.
   PubMed    
   
   
   
6. WATERS V, Ratjen F
   Reply to: Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.
   Eur Respir J. 2024;64:2401577.
   PubMed    
   
   
   
7. WATERS V, Quon B, Ratjen F
   Reply to: Steroids in cystic fibrosis exacerbations: are we picking the right patients?
   Eur Respir J. 2024;64:2401713.
   PubMed    
   
   
   
8. LIU Y, He KZ, Xu JF
   Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.
   Eur Respir J. 2024;64:2401049.
   PubMed    
   
   
   
9. BEINART D, Forrester DL, Ramakrishnan S
   Steroids in cystic fibrosis exacerbations: are we picking the right patients?
   Eur Respir J. 2024;64:2401225.
   PubMed    
   
   
   September 2024
10. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    PubMed     Abstract available
    
    
    
11. REIX P, Chassagnon G
    The younger, the better: lessons learned from real-world studies on CFTR modulators in young children.
    Eur Respir J. 2024;64:2401178.
    PubMed    
    
    
    
12. STAHL M, Dohna M, Graeber SY, Sommerburg O, et al
    Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles.
    Eur Respir J. 2024;64:2400004.
    PubMed     Abstract available
    
    
    
13. CHASSAGNON G, Burgel PR
    Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
    Eur Respir J. 2024;64:2401247.
    PubMed    
    
    
    
14. MIDDLETON PG, Simmonds NJ
    Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;64:2400929.
    PubMed    
    
    
    August 2024
15. IVY D, Rosenzweig EB, Abman SH, Beghetti M, et al
    Embracing the challenges of neonatal and paediatric pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401345. doi: 10.1183/13993003.01345-2024.
    PubMed     Abstract available
    
    
    
16. VARGHESE NP, Austin ED, Galambos C, Mullen MP, et al
    An Interdisciplinary Consensus Approach to Pulmonary Hypertension in Developmental Lung Disorders.
    Eur Respir J. 2024 Aug 15:2400639. doi: 10.1183/13993003.00639-2024.
    PubMed     Abstract available
    
    
    July 2024
17. ZANNIN E, Rigotti C, Schulzke SM, Sindelar R, et al
    Early respiratory system reactance predicts respiratory outcomes in preterm infants: a retrospective, multicentre study.
    Eur Respir J. 2024 Jul 26:2400246. doi: 10.1183/13993003.00246-2024.
    PubMed     Abstract available
    
    
    
18. AGARWAL S, Jat KR, Gupta S, Sankar J, et al
    Video-based direct observation physiotherapy in children with cystic fibrosis: a randomised controlled trial.
    Eur Respir J. 2024;64:2400826.
    PubMed    
    
    
    June 2024
19. GOSS CH, VanDevanter DR
    Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes.
    Eur Respir J. 2024;63:2400858.
    PubMed    
    
    
    
20. WATERS V, Shaw M, Perrem L, Quon BS, et al
    A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.
    Eur Respir J. 2024;63:2302278.
    PubMed     Abstract available
    
    
    May 2024
21. CAVERLY LJ, Ross BD, Dickson RP
    From gut to lung and back again: early life microbiota in cystic fibrosis.
    Eur Respir J. 2024;63:2400595.
    PubMed    
    
    
    April 2024
22. FURSTOVA E, Drevinek P, Novotna S, Libik M, et al
    Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay.
    Eur Respir J. 2024;63:2400156.
    PubMed    
    
    
    March 2024
23. FRAYMAN KB, Macowan M, Caparros-Martin J, Ranganathan SC, et al
    The Longitudinal Microbial and Metabolic Landscape of infant Cystic Fibrosis: The gut-lung axis.
    Eur Respir J. 2024 Mar 14:2302290. doi: 10.1183/13993003.02290-2023.
    PubMed     Abstract available
    
    
    
24. MCKONE EF
    Socioeconomic disparities in European cystic fibrosis outcomes: time to close the gap.
    Eur Respir J. 2024;63:2400328.
    PubMed    
    
    
    
25. XU X, Li JD, Green TJ, Wilson L, et al
    Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis.
    Eur Respir J. 2024;63:2301512.
    PubMed     Abstract available
    
    
    
26. KEREM E, Orenti A, Adamoli A, Hatziagorou E, et al
    Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.
    Eur Respir J. 2024;63:2301241.
    PubMed     Abstract available
    
    
    
27. WIELPUTZ MO, Mall MA
    Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Eur Respir J. 2024;63:2400234.
    PubMed    
    
    
    February 2024
28. COHEN R, Shteinberg M
    Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
    Eur Respir J. 2024;63:2400068.
    PubMed    
    
    
    
29. HOUSTON CJ, Alkhatib A, Einarsson GG, Tunney MM, et al
    Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.
    Eur Respir J. 2024;63:2301228.
    PubMed     Abstract available
    
    
    
30. DOONEY M, Saba T
    Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2301392.
    PubMed    
    
    
    
31. BURGEL PR
    Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2400233.
    PubMed    
    
    
    January 2024
32. BURGEL PR, Sermet-Gaudelus I, Girodon E, Kanaan R, et al
    Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint.
    Eur Respir J. 2024;63:2301959.
    PubMed    
    
    
    December 2023
33. SUNDE RB MD PHD, Thorsen J MD PhD, Kim M MSc PhD, Schoos AM MD PhD, et al
    Bacterial Colonization of the Airway in Neonates and Risk of Asthma and Allergy Until Age 18 Years.
    Eur Respir J. 2023 Dec 14:2300471. doi: 10.1183/13993003.00471-2023.
    PubMed     Abstract available
    
    
    
34. BARRY PJ, Burgel PR
    Cast no shadow: assessing the disease-modifying effects of elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2023;62:2302026.
    PubMed    
    
    
    
35. DAINES CL, Tullis E, Costa S, Linnemann RW, et al
    Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
    Eur Respir J. 2023;62:2202029.
    PubMed     Abstract available
    
    
    
36. SUCRE JMS, Frank DB
    Having new eyes: MRI for visualisation of pulmonary vascular disease and prediction of bronchopulmonary dysplasia severity.
    Eur Respir J. 2023;62:2302041.
    PubMed    
    
    
    November 2023
37. HYSINGER EB, Critser P
    How is preterm birth working out: cardiopulmonary response to exercise in extreme prematurity.
    Eur Respir J. 2023;62:2301787.
    PubMed    
    
    
    October 2023
38. WANG KCW, Elliot JG, Saglani S, Donovan GM, et al
    The airway smooth muscle layer is structurally abnormal in low birth weight infants - implications for obstructive disease.
    Eur Respir J. 2023 Oct 12:2301176. doi: 10.1183/13993003.01176-2023.
    PubMed    
    
    
    
39. BEEN JV, Simons SHP, Labrecque JA
    Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?
    Eur Respir J. 2023;62:2301473.
    PubMed    
    
    
    
40. BEAR C, Ratjen F
    Charting the path to expanded access for CFTR modulator drugs: the nose knows.
    Eur Respir J. 2023;62:2301387.
    PubMed    
    
    
    
41. DREANO E, Burgel PR, Hatton A, Bouazza N, et al
    Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
    Eur Respir J. 2023;62:2300110.
    PubMed     Abstract available
    
    
    
42. HEBESTREIT H, Thornton CS
    Cystic fibrosis and the cardiovascular system: the unexpected heartache.
    Eur Respir J. 2023;62:2301253.
    PubMed    
    
    
    
43. FROST F, Nazareth D, Fauchier L, Wat D, et al
    Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study.
    Eur Respir J. 2023;62:2300174.
    PubMed     Abstract available
    
    
    September 2023
44. DELFRATE J, Girard-Bock C, Curnier D, Perie D, et al
    Cardiopulmonary response to exercise in adults born very preterm.
    Eur Respir J. 2023 Sep 21:2300503. doi: 10.1183/13993003.00503-2023.
    PubMed     Abstract available
    
    
    
45. HAFNER F, Kindt A, Strobl K, Forster K, et al
    MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease.
    Eur Respir J. 2023 Sep 7:2202445. doi: 10.1183/13993003.02445-2022.
    PubMed     Abstract available
    
    
    
46. MORRISON L, Thornton CS
    Quality over quantity: the next ACT in airway clearance in cystic fibrosis.
    Eur Respir J. 2023;62:2301354.
    PubMed    
    
    
    
47. FILIPOW N, Stanojevic S, Raywood E, Shannon H, et al
    Real-world effectiveness of airway clearance techniques in children with cystic fibrosis.
    Eur Respir J. 2023;62:2300522.
    PubMed     Abstract available
    
    
    August 2023
48. KWOK TC, Szatkowski L, Sharkey D
    Impact of postnatal dexamethasone timing on preterm mortality and bronchopulmonary dysplasia: a propensity score analysis.
    Eur Respir J. 2023 Aug 17:2300825. doi: 10.1183/13993003.00825-2023.
    PubMed     Abstract available
    
    
    
49. POWELL WT, Reeves SR
    From small to big, using microRNA profiling to investigate infant origins of childhood asthma.
    Eur Respir J. 2023;62:2301052.
    PubMed    
    
    
    
50. TUNNEY MM, Wark P
    Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist.
    Eur Respir J. 2023;62:2301008.
    PubMed    
    
    
    
51. SCHAUPP L, Addante A, Voller M, Fentker K, et al
    Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
    Eur Respir J. 2023;62:2202153.
    PubMed     Abstract available
    
    
    July 2023
52. DONALDSON SH
    More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice.
    Eur Respir J. 2023;62:2300865.
    PubMed    
    
    
    
53. BAYFIELD KJ, Weinheimer O, Boyton C, Fitzpatrick R, et al
    Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease.
    Eur Respir J. 2023;62:2300286.
    PubMed     Abstract available
    
    
    
54. DWYER TJ, Elkins MR, Dentice R, Forbes S, et al
    Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline.
    Eur Respir J. 2023;62:2100960.
    PubMed     Abstract available
    
    
    June 2023
55. ZHU Z, Freishtat RJ, Harmon B, Hahn A, et al
    Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study.
    Eur Respir J. 2023 Jun 15:2300502. doi: 10.1183/13993003.00502-2023.
    PubMed     Abstract available
    
    
    
56. DUIJTS L
    Prematurity-related chronic respiratory disease across the life course.
    Eur Respir J. 2023;61:2300662.
    PubMed    
    
    
    May 2023
57. BEHR J
    The art of clinical trial design in pulmonary fibrosis.
    Eur Respir J. 2023;61:2300346.
    PubMed    
    
    
    
58. 
    May Podcast: Cystic fibrosis.
    Eur Respir J. 2023;61:23E6105.
    PubMed    
    
    
    
59. ADDANTE A, Raymond W, Gitlin I, Charbit A, et al
    A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
    Eur Respir J. 2023;61:2202022.
    PubMed     Abstract available
    
    
    April 2023
60. BRUSCIA EM
    The effects of elexafactor/tezafactor/ivacaftor beyond the epithelium: spurring macrophages to fight infections.
    Eur Respir J. 2023;61:2300216.
    PubMed    
    
    
    
61. CAVINATO L, Luly FR, Pastore V, Chiappetta D, et al
    Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.
    Eur Respir J. 2023;61:2200725.
    PubMed     Abstract available
    
    
    
62. ZHANG S, Shrestha CL, Robledo-Avila F, Jaganathan D, et al
    Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2023;61:2102861.
    PubMed     Abstract available
    
    
    
63. VAN TONDER AJ, Ellis HC, Churchward CP, Kumar K, et al
    M ycobacterium avium complex genomics and transmission in a London hospital.
    Eur Respir J. 2023;61:2201237.
    PubMed     Abstract available
    
    
    March 2023
64. PULAKKA A, Risnes K, Metsala J, Alenius S, et al
    Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries.
    Eur Respir J. 2023 Mar 29:2201763. doi: 10.1183/13993003.01763-2022.
    PubMed     Abstract available
    
    
    
65. DENHOLM JT
    Children and TB pharmacokinetics: no longer in infancy?
    Eur Respir J. 2023;61:2202003.
    PubMed    
    
    
    
66. ASMUS E, Karle W, Brack MC, Wittig C, et al
    Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.
    Eur Respir J. 2023;61:2202009.
    PubMed     Abstract available
    
    
    February 2023
67. PEDERSEN ESL, Kuehni CE
    Preventing bronchiolitis among infants with non-pharmaceutical interventions outside pandemics: is it realistic?
    Eur Respir J. 2023;61:2202214.
    PubMed    
    
    
    January 2023
68. DHOTE T, Martin C, Regard L, Pesenti L, et al
    Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis.
    Eur Respir J. 2023;61:2202096.
    PubMed    
    
    
    December 2022
69. RINGSHAUSEN FC, Sauer-Heilborn A, Buttner T, Dittrich AM, et al
    Lung transplantation for end-stage cystic fibrosis before and after the accessibility of elexacaftor/tezacaftor/ivacaftor, Germany, 2012-2021.
    Eur Respir J. 2022 Dec 14:2201402. doi: 10.1183/13993003.01402-2022.
    PubMed    
    
    
    
70. MITROPOULOU G, Brandenberg N, Hoehnel S, Ceroni C, et al
    Rectal organoid-guided CFTR modulator therapy restores lung function in a cystic fibrosis patient with the rare 1677delTA/R334W genotype.
    Eur Respir J. 2022;60:2201341.
    PubMed    
    
    
    November 2022
71. WILLERS CC, Frauchiger BS, Stranzinger E, Bauman G, et al
    Feasibility of unsedated lung MRI in young children with cystic fibrosis.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    September 2022
72. BONADIES L, Papi A, Baraldi E
    Is bronchopulmonary dysplasia in adult age a novel COPD endotype?
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
73. UM-BERGSTROM P, Pourbazargan M, Brundin B, Strom M, et al
    Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    August 2022
74. BIRKET SE
    A step forward for an intermediate cystic fibrosis population.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
75. NGUYEN-KHOA T, Hatton A, Drummond D, Aoust L, et al
    Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
76. SAFERALI A, Qiao D, Kim W, Raraigh K, et al
    C FTR variants are associated with chronic bronchitis in smokers.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    
77. MUILWIJK D, de Poel E, van Mourik P, Suen SWF, et al
    Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    July 2022
78. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
    Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
    PubMed     Abstract available
    
    
    
79. CHASSAGNON G, Campredon A, Vakalopoulou M, Burgel PR, et al
    Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
80. ZHANG B, Zhang S
    Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    May 2022
81. RIGAUTS C, Aizawa J, Taylor SL, Rogers GB, et al
    R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    March 2022
82. ZANNIN E, Rigotti C, Neumann RP, Dellaca RL, et al
    Oscillatory mechanics at 36 weeks post-menstrual age as markers of lung disease in preterm infants: a cohort study.
    Eur Respir J. 2022 Mar 2. pii: 13993003.03023-2021.
    PubMed    
    
    
    
83. KURZ JM, Ramsey KA, Rodriguez R, Spycher B, et al
    Association of lung clearance index with survival in individuals with cystic fibrosis.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    February 2022
84. YEH HI, Hwang TC
    In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    
85. HIRANI D, Alvira CM, Danopoulos S, Milla C, et al
    Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    
86. GOSS CH, Fajac I, Jain R, Seibold W, et al
    Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    
87. MORRISON CB, Shaffer KM, Araba KC, Markovetz MR, et al
    Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    December 2021
88. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
    Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
    PubMed     Abstract available
    
    
    
89. GURDENIZ G, Ernst M, Rago D, Kim M, et al
    Neonatal metabolome of cesarean section and risk of childhood asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
    PubMed     Abstract available
    
    
    
90. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
    Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
    Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
    PubMed     Abstract available
    
    
    
91. REEVES SR
    Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
92. SETTE G, Lo Cicero S, Blacona G, Pierandrei S, et al
    Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    November 2021
93. BINGLE CD, Bingle L
    SPLUNC1 comes of age? Predicting acute exacerbations in cystic fibrosis.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
94. KHANAL S, Webster M, Niu N, Zielonka J, et al
    SPLUNC1: a novel marker of cystic fibrosis exacerbations.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    October 2021
95. SATRELL E, Clemm H, Roksund O, Hufthammer KO, et al
    Development of lung diffusion to adulthood following extremely preterm birth.
    Eur Respir J. 2021 Oct 8. pii: 13993003.04103-2020.
    PubMed     Abstract available
    
    
    September 2021
96. HART K, Cousins M, Watkins WJ, Kotecha SJ, et al
    Association of Early Life Factors with Prematurity-Associated Lung Disease: Prospective Cohort Study.
    Eur Respir J. 2021 Sep 29. pii: 13993003.01766-2021.
    PubMed     Abstract available
    
    
    
97. MARTIN C, Burgel PR
    Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
98. MCKONE EF, Ariti C, Jackson A, Zolin A, et al
    Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    July 2021
99. WECKMANN M, Bahmer T, Bulow Sand JM, Rank Ronnow S, et al
    COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.
    Eur Respir J. 2021 Jul 29. pii: 13993003.03969-2020.
    PubMed     Abstract available
    
    
    June 2021
100. CORIATI A, Sykes J, Lemonnier L, Ma X, et al
     The impact of the high emergency lung transplantation program in cystic fibrosis in France: insight from a comparison with Canada.
     Eur Respir J. 2021 Jun 17. pii: 13993003.00014-2021.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neonatology is free of charge.